Cardiff Oncology, Inc. Q4 FY2023 earnings call

• Shifted mCRC program from second-line to first-line due to clinical signal, new mechanism of action, and FDA support. • Shared ONSEMBLE trial data supporting first-line strategy, including bev naïve patients showing robust responses with onvansertib plus standard of care. • Announced Pfizer Ignite program for CRDF-004 trial. • Provided updates on other trials: pancreatic cancer trial with three confirmed partial responses from initial four, and small lung cancer trial with first clinical data using onvansertib as single agent. • Discussed mechanism of action of onvansertib in the HIF1α pathway, complementary to bevacizumab.

• Cash resources provide cash runway into Q3 2025. • CRDF-004 trial expected to release data in mid-2024 with objective response rate data for approximately half the enrolled patients.

• Forward-looking statements involve significant risks and uncertainties, including factors described in the Risk Factors section of the 10-K filed with the SEC.

Q: Any sense for how much data from the CRDF-004 trial will be released in mid-2024?

A: Will release data when there's approximately half the patients enrolled, with at least one scan after baseline.

Q: Performed PFS analysis on ONSEMBLE data?

A: Not rigorously done yet due to small number of patients, but there appears to be an emergent PFS signal.

Q: Safety run-in for FOLFOX in frontline trial?

A: First nine patients dosed will be evaluated by safety committee; no major toxicity expected.

Q: Updates on small cell lung cancer trial?

A: PI moved to another institution, slowing accrual.